Novanta Inc.

NOVT

$147.24

+1.88%

N/A+$2.72

Technology

Hardware, Equipment & Parts

NASDAQ

Active Trading

Operating globally, Novanta Inc. and its affiliated companies specialize in the development, production, and distribution of advanced photonics, vision, and precision motion ...

Fundamental Analysis of NOVT

Key Strengths

Strong R&D investment (9.1% of revenue) driving innovation in photonics, vision, and precision motion.

High gross margin of 42.5%, indicating pricing power and product differentiation.

Risk Factors

High valuation: P/E of 105.1 and EV/EBITDA of 39.5 may limit upside potential and increase downside risk.

Dependence on highly regulated medical device industry, where approval processes can be lengthy and costly.

Profitability

Net Margin6.00%

Operating Margin10.43%

Valuation

P/E Ratio92.60x

Current Ratio4.57

Efficiency

ROE4.90%

ROA2.89%

Fundamental Analysis of NOVT

Novanta Inc. is a leading supplier of advanced photonics, vision, and precision motion technologies for medical and industrial OEMs. The company has demonstrated a strong commitment to innovation, with R&D spending representing 9.1% of revenue, underpinning its competitive moat in high-precision applications. Financially, Novanta exhibits solid profitability, with a gross margin of 42.5% and an operating margin of 10.4%, reflecting its ability to generate value from its engineered solutions. The balance sheet is conservative, with a debt-to-equity ratio of 17.5% and a strong current ratio of 4.57, indicating ample liquidity. However, the company's valuation appears stretched, with a trailing P/E of 105.1 and EV/EBITDA of 39.5, significantly above historical averages and industry peers. This elevated valuation suggests that the market expects substantial future growth, likely driven by secular trends in surgical robotics, DNA sequencing, and advanced manufacturing. Growth metrics are positive, with revenue per share of $25.11 and improving efficiency as evidenced by a cash conversion cycle of 122 days, although this is relatively high. The company's near-zero dividend payout reflects a reinvestment strategy, which is typical for growth-oriented firms. Overall, Novanta's fundamentals are sound, but the premium valuation poses a risk if growth decelerates. Analyst consensus remains bullish, with a 'strong buy' rating, reflecting confidence in the company's long-term prospects. The main challenges include regulatory hurdles in medical devices, supply chain complexities, and intense competition from larger players. Despite these risks, Novanta's specialized expertise and customer relationships in high-growth niches provide a solid foundation for sustained growth.

Key Strengths of NOVT

Strong R&D investment (9.1% of revenue) driving innovation in photonics, vision, and precision motion.
High gross margin of 42.5%, indicating pricing power and product differentiation.
Robust liquidity with current ratio of 4.57 and cash ratio of 2.92, providing financial flexibility.
Conservative leverage with a debt-to-equity ratio of 17.5%, reducing financial risk.
Diversified portfolio across medical and industrial sectors, reducing dependency on any single end-market.
Exposure to high-growth trends like surgical robotics, DNA sequencing, and semiconductor manufacturing.
Proven track record of operational excellence through the Novanta Growth System.
Solid insider ownership and strong management team with deep industry expertise.

Risk Factors of NOVT

High valuation: P/E of 105.1 and EV/EBITDA of 39.5 may limit upside potential and increase downside risk.
Dependence on highly regulated medical device industry, where approval processes can be lengthy and costly.
Concentration of revenue among a limited number of large OEM customers, posing a risk if customer losses occur.
Exposure to global supply chain disruptions, given the company's sourcing of high-tech components.
Intense competition from larger players like Danaher and ZEISS, which have more extensive resources.
Potential impact of foreign exchange fluctuations, as a significant portion of revenue is generated internationally.
Cyclicality in the industrial sector, which could affect demand for precision motion and photonics products.
Integration risks associated with acquisitions, which have been a key part of the company's growth strategy.

Market Cap vs Revenue & Earnings

Earnings

n/a

Revenue

n/a

Market cap

$5.24B

92.6x

P/E Ratio

5.1x

P/S Ratio

Earnings & Revenue

Last Reportedn/a

Earnings per share (EPS)n/a

Gross Margin42.52%

Net Profit Margin6.00%

Debt/Equity Ratio0.17

Profitability Bridge (Current vs YoY)

How gross, operating and net margins shifted versus last year.

Revenue / Net Income / FCF History (USD B)

Growth Signals of NOVT

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Revenue	—	—	—	—	Flat
Diluted EPS	—	—	—	—	Flat
Free Cash Flow	—	—	—	—	Flat

Profitability of NOVT

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Net Margin	—	4.72%	—	—	Flat
Operating Margin	—	6.79%	—	—	Flat
ROE	—	—	—	—	Flat

Financial Health of NOVT

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Current Ratio	—	4.569	—	—	Flat
Quick Ratio	—	3.786	—	—	Flat
Debt / Equity	—	0.175	—	—	Flat

Valuation of NOVT

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
P/E	—	130.42x	—	—	Flat
P/B	—	4.10x	—	—	Flat

Supply Chain of NOVT

RELATIONS

Upstream

Impinj Inc.NASDAQ:PI NXP Semiconductors N.V.NASDAQ:NXPI Identiv Inc.NASDAQ:INVE AMD Inc. (Xilinx)NASDAQ:AMD Texas Instruments Inc.NASDAQ:TXN Analog Devices Inc.NASDAQ:ADI Microchip Technology Inc.NASDAQ:MCHP Infineon Technologies AGOTC:IFNNY onsemiNASDAQ:ON Coherent Corp.NASDAQ:COHRSchneider Electric SEEPA:SUTrimble Inc.NASDAQ:TRMB

Downstream

Intuitive Surgical Inc.NASDAQ:ISRG Stryker CorporationNYSE:SYK Medtronic plcNYSE:MDT Johnson & JohnsonNYSE:JNJSiemens Healthineers AGETR:SHLGE HealthCare Technologies Inc.NASDAQ:GEHC FANUC CorporationOTC:FANUY ABB LtdNYSE:ABB Teradyne Inc. (via Universal Robots)NASDAQ:TER Cognex CorporationNASDAQ:CGNXInmoco LtdAcal BFiLSE:ACLRS Group plc (RS Components)LSE:RS1Riverpoint Medical

Proxies

MKS Instruments Inc.NASDAQ:MKSI Coherent Corp.NASDAQ:COHR Sensata Technologies Holding plcNYSE:ST Cognex CorporationNASDAQ:CGNX Nordson CorporationNASDAQ:NDSN

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer